Navigation Links
Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
Date:5/5/2009

Development of the seasonal influenza virus-like particle (VLP) vaccine progresses with study designed to select dose for Phase III efficacy trial

ROCKVILLE, Md., May 5 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today vaccination of healthy volunteers in the second clinical trial of its virus-like particle (VLP) seasonal influenza vaccine. Building on data from the first study, this Phase II randomized, placebo controlled clinical trial has been designed to evaluate the safety and immunogenicity of a broader range of vaccine doses. The purpose of this study is to provide data to help with selecting doses for future studies in older adults and a Phase III efficacy study. Specifically, the trivalent seasonal vaccine containing VLPs against the 2008-2009 H3N2, H1N1, and B influenza strains will be studied in approximately 220 healthy adults between the ages of 18 to 49 years, who will receive a single injection of either a placebo or influenza vaccine at doses of 15 mcg or 60 mcg. As announced in December, 2008, a Phase II dose ranging clinical trial conducted by Novavax in ~300 healthy volunteers with VLPs against the 2005-2006 H3N2, H1N1, and B influenza strains showed that the trivalent VLP vaccine candidate induced robust immune responses as measured by hemagglutinin inhibition titers against both vaccine and drifted strains.

According to the Centers for Disease Control and Prevention (CDC), seasonal influenza affects 15 to 60 million people in the United States each year and is responsible for an estimated 200,000 hospitalizations and approximately 36,000 deaths. The VLP-based seasonal influenza vaccine may be another important public health weapon to fight this disease. VLPs contain 3 proteins that are important for inducing a broad immune response against influenza -- the hemagglutinin or "HA" and th
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
2. Novavax Announces Early Retirement of $17 Million of Convertible Debt
3. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
4. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
5. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
6. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
8. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
9. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
10. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
11. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in whole ... to do so would constitute a violation of the relevant ... the "Company") (LSE: SHP, NASDAQ: SHPG ) notes ... a meeting with representatives of AbbVie. This statement ... approval of AbbVie. A further update will be ...
(Date:7/11/2014)... 11, 2014  Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/10/2014)... Understanding the need for better quality ... the gap that currently exists in this area, ChanTest ... portfolio of validated ion channel and GPCR cell lines. ... as ion channels control many critical physiological functions throughout ... the potential to treat a variety of human diseases. ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... HILLS, Mass., Dec. 5 MacroChem,s,(OTC Bulletin Board: MACM), ... at the upcoming Equities Magazine Winter Discovery,Day Conference XV ... December 7,2007. Mr. DeLuccia is scheduled to present at ... an all day event featuring special,presentations from emerging public ...
... Md., Dec. 5 Micromet, Inc. (Nasdaq:,MITI), a ... antibody-based products for cancer, inflammation and autoimmune,diseases, today ... Officer of Micromet, will be part of a ... Therapies For Cancer" at the 2007,RBC Capital Markets ...
... Dec. 5 Nastech Pharmaceutical,Company Inc. (Nasdaq: NSTK ... study with an undisclosed global leader in the production ... Factor IX protein,which is currently administered by injection to ... "We look forward to working with our new global ...
Cached Biology Technology:MacroChem to Present at Equities Magazine Conference December 7, 2007 in New York 2MacroChem to Present at Equities Magazine Conference December 7, 2007 in New York 3Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007 2Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding 2
(Date:7/11/2014)... animals often develop relationships with other group members to ... wild chacma baboons the strategy for grooming activities shows ... just published in the scientific journal Biology Letters ... baboons is not practiced without ulterior motives. To be ... the individual, while grooming another individual can provide access ...
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
(Date:7/11/2014)... 1 can inhibit voltage-gated calcium channel, decrease ... However, some scholars demonstrated that cannabinoid receptor ... and increase neurotransmitter release. Dr. Yi Zhang ... Tongji Medical College, Huazhong University of Science ... and calcium imaging in cultured trigeminal ganglion ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... researcher, please contact the Communications and External Relations staff member ... on ORNL and its research and development activities, please refer ... general media-related question or comment, you can send it to ... fuel pellets . . . Oak Ridge ...
... Spain: The numbers of cycles of preimplantation genetic diagnosis ... 2,700 reported in 2004 (the most recent year for ... screen for a growing number of genetically related conditions, ... the targeted condition are available for transfer and the ...
... that gladdens a mother,s heart also lights up the reward ... in a report that appears in the journal Pediatrics ... out the special mother-infant bond and how it sometimes go ... BCM and Texas Children,s Hospital and a research associate in ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 3Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 2Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 3A baby's smile is a natural high 2
... GenePix Pro is the industry standard ... unique combination of imaging and analysis tools, ... use. GenePix Pro is included with every ... images from third-party scanners and all types ...
... the one mouse-click image analysis software ... It is the solution for high ... images. MicroVigene is empowered with VigeneTechs ... grid, regional 2D-curve fitting background correction ...
... For applications not requiring confocal, the ... alternative to the Pathway 435. And, the ... if later applications require it. ... can elect to use the laser autofocus, ...
... Proteomic Imaging System, Professional Package Superior ... Dynamic Range: The ProXPRESS 2D Proteomic Imaging ... system for both proteomic and general life ... flexibility, enabling the use of all dyes ...
Biology Products: